Ionic liquids for internal delivery

Abstract

The technology described herein is directed to compositions comprising CAGE and at least one active compound, e.g., for oral or parenteral administration.

1 .- 142 . (canceled) 
     
     
         143 . A method of delivery of at least one active compound to a subject in need thereof, the method comprising subcutaneously administering a composition comprising Choline and Geranate or Geranic Acid (CAGE) in combination with the at least one active compound to the subject. 
     
     
         144 . The method of  claim 143 , wherein the CAGE is at a concentration of at least 0.1% w/v. 
     
     
         145 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 2:1 to about 1:10. 
     
     
         146 . The method of  claim 143 , wherein the at least one active compound comprises a nucleic acid molecule, a small molecule, a polypeptide, an antibody, an antibody reagent, or a chemotherapeutic compound. 
     
     
         147 . The method of  claim 143 , wherein the composition further comprises a pharmaceutically acceptable carrier. 
     
     
         148 . The method of  claim 143 , wherein the combination of the at least one active compound and CAGE is an admixture. 
     
     
         149 . The method of  claim 146 , wherein the at least one active compound comprises an antibody or antibody reagent. 
     
     
         150 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 1:1 to about 1:4. 
     
     
         151 . The method of  claim 143 , wherein the CAGE comprises a ratio of Choline:Geranate or Geranic Acid of from about 1:2 to about 1:5. 
     
     
         152 . The method of  claim 143 , wherein the composition is administered once. 
     
     
         153 . The method of  claim 143 , wherein the composition is administered in multiple doses. 
     
     
         154 . The method of  claim 146 , wherein the at least one active compound comprises a chemotherapeutic compound. 
     
     
         155 . The method of  claim 143 , wherein the at least one active compound is provided at a dosage of 1-20 mg/kg. 
     
     
         156 . The method of  claim 143 , whereby the administration provides a systemic effect to the subject.